Previous studies on KRAS expression have shown a discrepancy between the primary tumour and corresponding lymph node metastases [16,17], whereas the expression of other biomarkers, e.g. ER and HER-2 in breast cancer have been demonstrated to be highly concordant [18]. This evidence concerns the gene ERBB2 and breast cancer.